A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis
Latest Information Update: 22 Oct 2021
Price :
$35 *
At a glance
- Drugs Anti-CD19 and anti-BCMA CART cell therapy-Yake Biotechnology (Primary)
- Indications Nephritis
- Focus Adverse reactions
- 22 Oct 2021 New trial record